- Status:
- Topic prioritisation
- Technology type:
- Medicine
- Decision:
- Not selected
- Prioritisation programme:
- Medicines evaluation
- Rationale:
Guselkumab is a paediatric extension of existing TA521. NHS England will commission treatments for patients aged less than 18 years where specific commissioning conditions are met as per the Commissioning Medicines for Children in Specialised Services policy. Therefore, a technology appraisal is not required for this medicine.
- ID number:
- 12002
Project Team
- Project lead
- Danielle.Lees@nice.org.uk
Email enquiries
If you have any queries please email topic.selection@nice.org.uk
For further information on how we select topics for development, please see our page about topic prioritisation